Cartesian Therapeutics (RNAC) Competitors $17.02 -0.10 (-0.58%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RNAC vs. NTLA, EVO, IMCR, OCUL, RCUS, KNSA, SPRY, XNCR, DAWN, and PRAXShould you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Intellia Therapeutics (NTLA), Evotec (EVO), Immunocore (IMCR), Ocular Therapeutix (OCUL), Arcus Biosciences (RCUS), Kiniksa Pharmaceuticals (KNSA), ARS Pharmaceuticals (SPRY), Xencor (XNCR), Day One Biopharmaceuticals (DAWN), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Cartesian Therapeutics vs. Intellia Therapeutics Evotec Immunocore Ocular Therapeutix Arcus Biosciences Kiniksa Pharmaceuticals ARS Pharmaceuticals Xencor Day One Biopharmaceuticals Praxis Precision Medicines Cartesian Therapeutics (NASDAQ:RNAC) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, community ranking, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Do institutionals and insiders hold more shares of RNAC or NTLA? 86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 57.9% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 3.2% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, RNAC or NTLA? Cartesian Therapeutics has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Is RNAC or NTLA more profitable? Intellia Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cartesian Therapeutics-510.72% N/A -6.03% Intellia Therapeutics N/A -49.34%-40.27% Do analysts rate RNAC or NTLA? Cartesian Therapeutics presently has a consensus price target of $42.33, suggesting a potential upside of 148.73%. Intellia Therapeutics has a consensus price target of $55.36, suggesting a potential upside of 266.12%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Intellia Therapeutics 0 Sell rating(s) 5 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.75 Does the MarketBeat Community prefer RNAC or NTLA? Intellia Therapeutics received 405 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 96.43% of users gave Cartesian Therapeutics an outperform vote while only 69.34% of users gave Intellia Therapeutics an outperform vote. CompanyUnderperformOutperformCartesian TherapeuticsOutperform Votes2796.43% Underperform Votes13.57%Intellia TherapeuticsOutperform Votes43269.34% Underperform Votes19130.66% Does the media prefer RNAC or NTLA? In the previous week, Intellia Therapeutics had 12 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 27 mentions for Intellia Therapeutics and 15 mentions for Cartesian Therapeutics. Intellia Therapeutics' average media sentiment score of 0.36 beat Cartesian Therapeutics' score of 0.25 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Intellia Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, RNAC or NTLA? Cartesian Therapeutics has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$54.10M8.00-$219.71M-$52.83-0.32Intellia Therapeutics$43.09M35.74-$481.19M-$5.44-2.78 SummaryIntellia Therapeutics beats Cartesian Therapeutics on 11 of the 19 factors compared between the two stocks. Ad Crypto 101 MediaMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…Click here to reserve your free seat at the Crypto Community Summit Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAC vs. The Competition Export to ExcelMetricCartesian TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$432.56M$7.05B$5.41B$8.88BDividend YieldN/A8.03%5.02%4.04%P/E Ratio-0.3211.53124.9617.46Price / Sales8.00348.331,253.4892.99Price / CashN/A49.2239.9136.42Price / Book567.339.086.315.86Net Income-$219.71M$154.47M$120.02M$225.23M7 Day Performance-18.02%-2.36%-1.26%-0.89%1 Month Performance-17.50%3.10%2.23%3.72%1 Year PerformanceN/A36.17%35.71%26.41% Cartesian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNACCartesian Therapeutics2.9539 of 5 stars$17.02-0.6%$42.33+148.7%N/A$432.56M$54.10M-0.3237High Trading VolumeNTLAIntellia Therapeutics4.5571 of 5 stars$17.26+3.2%N/A-42.8%$1.75B$36.28M-3.17600Earnings ReportAnalyst ForecastAnalyst RevisionGap DownEVOEvotec1.7822 of 5 stars$4.89+18.4%N/A-49.4%$1.73B$845.74M0.005,061Short Interest ↓Analyst RevisionNews CoverageTrading HaltedHigh Trading VolumeIMCRImmunocore2.5643 of 5 stars$34.34-1.0%N/A-33.4%$1.72B$296.31M-36.15497Analyst DowngradeAnalyst RevisionOCULOcular Therapeutix4.0209 of 5 stars$10.88-2.0%N/A+350.9%$1.70B$58.44M-8.06267News CoverageRCUSArcus Biosciences2.9276 of 5 stars$18.13+1.6%N/A+9.6%$1.66B$117M-5.76500Gap UpKNSAKiniksa Pharmaceuticals2.0862 of 5 stars$22.93+0.3%N/A+36.7%$1.66B$270.26M-163.77220Positive NewsSPRYARS Pharmaceuticals2.63 of 5 stars$17.04flatN/A+233.6%$1.65B$30,000.00-36.2690Insider SellingNews CoverageHigh Trading VolumeXNCRXencor3.6103 of 5 stars$23.52-0.4%N/A+27.3%$1.65B$168.34M-7.35280Insider SellingAnalyst RevisionNews CoverageDAWNDay One Biopharmaceuticals1.7714 of 5 stars$15.94-2.7%N/A+17.7%$1.61BN/A-15.4860Insider SellingShort Interest ↑PRAXPraxis Precision Medicines1.4191 of 5 stars$83.68+7.4%N/A+458.5%$1.56B$1.61M-8.12110 Related Companies and Tools Related Companies NTLA Competitors EVO Competitors IMCR Competitors OCUL Competitors RCUS Competitors KNSA Competitors SPRY Competitors XNCR Competitors DAWN Competitors PRAX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RNAC) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAC Stock Alerts